Ubiquitin Ligase COP1 マイクログリアでc/EBPβを分解することによって神経炎症を抑制する
Ada Ndoja1, Rohit Reja2, Seung-Hye Lee3
1Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.
Cell
|August 16, 2020
まとめ
通常COP1は マイクログリアの有害な遺伝子活動を抑制します これはアルツハイマー病のような 神経変性における重要な細胞です c/EBPβが蓄積され,神経炎症とタウ病気が悪化する.
科学分野:
- 神経科学
- 免疫学
- 遺伝学
背景:
- 脳の免疫細胞であるマイクログリアは アルツハイマー病のような 神経退行性疾患に関与しています
- 転写因子CCAAT/強化結合タンパク質β (c/EBPβ) はマイクログリアの炎症を促進し,ADでは上昇する.
- 有害なマイクログリアル遺伝子発現を制御するメカニズムは完全に理解されていません.
研究 の 目的:
- 特にc/EBPβに焦点を当てて,マイクログリアル遺伝子発現の調節におけるユビキチンリガゼCOP1 (RFWD2) の役割を調査する.
- マイクログリアの炎症反応と神経毒性に対するCOP1欠乏の影響を決定する.
- 神経変性に対するマイクログリアの貢献におけるCOP1の機能を明らかにする.
主な方法:
- c/EBPβのCOP1による翻訳後の調節がマイクログリアで研究された.
- マイクログリア-ニューロン共同培養は神経毒性を評価するために使用され,抗体阻害は媒介者を特定するために使用された.
- COP1欠乏とCebpbアレル喪失の影響を研究するために,遺伝子発現分析とタウ媒介神経変性マウスモデルを使用した.
主要な成果:
- COP1はマイクログリア内のc/EBPβタンパク質のレベルを調節する.
- COP1の欠乏はc/EBPβの蓄積につながり,主に補充によって媒介される炎症性および神経毒性遺伝子プログラムを駆動する.
- 一つのCebpbアレルの喪失は,炎症性フェノタイプを緩和しました.
- COP1欠乏症のマイクログリアは,タウ媒介の神経変性 in vivoで悪化した.
結論:
- COP1は,病原性c/EBPβ依存遺伝子発現プログラムの重要な抑制剤として作用する.
- COP1-c/EBPβ軸をターゲットにすることで,マイクログリア活性化によって引き起こされる神経変性疾患の治療戦略を提供することができる.
関連する概念動画
Receptor Downregulation in MVBs
2.6K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.6K
Regulation of the Unfolded Protein Response
2.8K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.8K
Regulated Protein Degradation
8.5K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.5K
Regulated Protein Degradation
2.9K
2.9K
NF-κB-dependent Signaling Pathway
9.6K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.6K
The Proteasome
1.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.4K


